Freyr Regulatory Radio

Freyr Regulatory Radio

Freyr is a leading, niche, full-service global Regulatory Solutions, and Services Company supporting, Large, Medium, and Small size global Life sciences companies, (Pharmaceutical | Generics | Medical Device | Biotechnology | Biosimilar | Consumer Healthcare | Cosmetics | Food and Food Supplements | Chemicals) in their entire Regulatory value-chain; ranging from Regulatory Strategy, Intelligence, Dossiers, Submissions, etc. to Post- Approval / Legacy Product Maintenance, Labeling, Artwork Change Management, and other related functions.

Episodes

September 26, 2023 9 mins

In the last episode of Freyr Regulatory Radio, Season 4, our experts discuss key considerations for Comparative Quality Studies for a proposed biosimilar product in the EU.

Furthermore, this episode throws light upon the criteria for the reference biological products and its evaluation.

To know more about Season 4, visit: https://www.freyrsolutions.com/regulatory-radio/season-4-eu-regulatory-pathways-for-biological-products 

Mark as Played

Streamlined biologic product development involves proper Regulatory assessment and overcoming challenges encountered during the CMC development phase. This episode will discuss the challenges faced during complex biological product development.

Furthermore, our experts will express their Regulatory views on variability in batch-to-batch testing, impurities testing, viral load clearance, and factors encountered in the biological pro...

Mark as Played

Biological product development involves proper planning and experimentation. Comprehending the biological CMC requirements is one such critical aspect during its development. This episode will detail the specifications required during biologics/biosimilar development.

Our experts will also share insights on the steps involved in the characterization of biological products, expression systems, and related details. 

Mark as Played

Episode 2 will detail the various guidelines for biological product development and approval in the market. The reference guidelines discussed in the podcast will include the following:

  • Guidelines that describe the expression construct, cloning, cell bank preparation, and characterization of biological products.
  • Guidelines to be referred for biologics drug substance development and manufacturing.
  • Guidelines to be referred for v...
Mark as Played

Introduction to Biologics and Biosimilars is the core of this episode. Our Regulatory experts will give an overview of the different Regulatory approval pathways for Biologics and Biosimilars in the EU. Additionally, they will discuss the significance and requirements of Regulatory submissions and scientific advice during the Regulatory processes.

To know more about the Season 4: EU Regulatory Pathways for Biological Products, visi...

Mark as Played

The Regulatory Affairs Life Cycle Management of a drug is considerably different from other commodities. The Office of the Lifecycle of Drug Products, a department under the Office of Pharmaceutical Quality (OPQ) under CDER, oversees the responsibility of delivering quality medicines to the population. Our experts elaborate on the subdivisions and their responsibilities toward the safety and efficacy of medications.

To know more ab...

Mark as Played

Patents are non-tangible assets for an organization/individual. To safeguard the innovator’s rights, the US FDA follows a unique patenting pathway for innovations. The United States Patent and Trademark Office (USPTO) looks after the awarding and verification of Intellectual Proprietary Rights. Our experts enlist various exclusivity periods stated under different designations and more.

To know more about Season 3, visit https://www...

Mark as Played

Expedited drug development pathways ensure the availability of treatment at the earliest. The US FDA’s facilitated Regulatory pathways give priority to innovators based on the nature of their innovation and more. Our experts discuss (i) Fastrack, (ii) Breakthrough Therapy, (iii) Accelerated Approval, and (iv) Priority Review and their impact on drug development timelines.

To know more about Season 3, visit https://www.freyrsolution...

Mark as Played

Understanding the unique benefits of standard drug approval pathways by the US FDA. Our experts talk about the importance of the different stages of drug development, right from the drug discovery/conceptual phase, pre-clinical phase, and clinical phase to the FDA review.

To know more about Season 3, visit https://www.freyrsolutions.com/regulatory-radio/season-3-us-market-entry 

Mark as Played

Establishment of the GDUFA and PDUFA guidelines and their impact on innovators and generics. Our experts discuss various merits of the guidelines and the significant changes signed into the law with each latest amendment.

To know more about Season 3, visit https://www.freyrsolutions.com/regulatory-radio/season-3-us-market-entry 

Mark as Played

Introduction to the USFDA framework and the cascade of events ultimately lead to authorization to market a drug product. Our experts elaborate on every department under the US FDA, focusing on the CBER and the CDER.  To know more about Season 3, visit https://www.freyrsolutions.com/regulatory-radio/season-3-us-market-entry 

Mark as Played

The pharmaceutical advertising in Canada for prescription drugs has always been under scrutiny as laws governing Direct-to-Consumer (DTC) advertisements of prescription-only medicines are misunderstood by organizations. The governing authority for medicines, Health Canada, is responsible for general advertisement and promotions. Our host highlights the laws and regulations laid down by Health Canada.   

Tune into other episodes of ...

Mark as Played

The Mexican pharmaceutical promotional regulations for advertising drugs, governed by the Federal Commission for the Protection from Sanitary Risks (COFEPRIS), are subjected to specific requirements to protect Healthcare Professionals (HCPs) and consumers from any associated risks. In this episode, our host describes the general requirements of drugs from an advertising perspective, legislated and issued by the Code of Conduct. 

Tu...

Mark as Played

Post-Brexit, the United Kingdom’s advertising review team scrutinizes published advertising in selected media, and we investigate referrals from colleagues in the Agency or other Regulatory Authorities. Our host addresses the necessary pharmaceutical advertising regulations a pharmaceutical organization must follow to ensure that the advertising material is thoroughly reviewed before the issue, thus avoiding misleading messages and...

Mark as Played

The Republic of Lithuania reflects good economic fortune for medicine manufacturers’ regional investments. To explore the Lithuanian market, manufacturers must obtain approvals from the State Medicines Control Agency. Our host gives us an insight into the Regulatory framework involved in the successful advertising and promotion of medicines.

Tune into other episodes of Season 2: https://www.freyrsolutions.com/regulatory-radio/seaso...

Mark as Played

Pharmaceutical advertisement in Australia is self-regulated or co-regulated, with various bodies having their codes relevant to the promotion of drugs. Our host gives a fair understanding of how the Regulatory environment can present a challenge for companies bringing new products to the market and promoting them.

Tune into other episodes of Season 2: https://www.freyrsolutions.com/regulatory-radio/season-2-pharma-advertising-and-p...

Mark as Played

A considerable grey area exists between providing information and promoting medicines in a semi-regulated market like Zimbabwe. Our host explores the pharmaceutical laws and regulations laid down by the Medicines Control Agency of Zimbabwe and elaborates on the key takeaways from the advertising legislative framework.

Tune into other episodes of Season 2: https://www.freyrsolutions.com/regulatory-radio/season-2-pharma-advertising-a...

Mark as Played

Welcome to Regulatory Radio, brought to you by Freyr Solutions. In the second season, we discuss the ad promo laws and regulations, offering a consolidated and high-level understanding of the laws in regulated and semi-regulated markets. With dynamic changes in the jurisdictions, compliance with the defined laws and interpretation of the concerned Health Authorities is essential.

Advertising of drugs has been a common practice adop...

Mark as Played

Health Authorities have accomplished major milestones in the previous decades. Fast-tracked approval of necessary medical products during the pandemic has set a benchmark for Regulatory Authorities to deliver safe and carefully examined medicines to the general population. Such efforts have set into motion a cascade of innovation and experimentation in the future of regulations and compliance. Our experts discuss diverse possibilit...

Mark as Played

Time-to-market plays a major role in addressing the needs of vulnerable patient groups. Facilitated pathways across the globe accelerate the timelines of innovative drug molecules, allowing fast-tracked approval pathways for essential medicines. Our experts address the necessary requirements of innovators and elaborate on the facilitated Regulatory pathways.

Reference Links

Mark as Played

Popular Podcasts

    Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.

    BG2Pod with Brad Gerstner and Bill Gurley

    Open Source bi-weekly conversation with Brad Gerstner (@altcap) & Bill Gurley (@bgurley) on all things tech, markets, investing & capitalism

    Crime Junkie

    If you can never get enough true crime... Congratulations, you’ve found your people.

    Stuff You Should Know

    If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

    The Breakfast Club

    The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy, Jess Hilarious And Charlamagne Tha God!

Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2024 iHeartMedia, Inc.